Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: Analogy between angina pectoris and solid tumors and enhancement of the EPR effect

Journal of Controlled Release

Volumn 142, Issue 3, 2010, Pages 296-298

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; CISPLATIN; GLYCERYL TRINITRATE; IODINATED POPPYSEED OIL; NAVELBINE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRITE; PROTOPORPHYRIN ZINC; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ANGINA PECTORIS; BLOOD FLOW; CANCER TISSUE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; EDITORIAL; HUMAN; HYPOXEMIA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR VASCULARIZATION;

ANGINA PECTORIS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD FLOW VELOCITY; CONTRAST MEDIA; CORONARY CIRCULATION; DRUG CARRIERS; HUMANS; HYPERTENSION; IODIZED OIL; MYOCARDIUM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITROGLYCERIN; PERMEABILITY;

EID: 77349118467     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.01.002     Document Type: Editorial

References (36)

1. Maki S., Konno T., and Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56 (1985) 751-757
2. Konno T., Maeda H., Iwai K., et al. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54 (1984) 2367-2374
3. Maeda H., Sawa T., and Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74 (2001) 47-61
4. Suzuki M., Hori K., Abe I., Saito S., and Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67 (1981) 663-669
5. Li C.J., Miyamoto Y., Kojima Y., and Maeda H. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer 67 (1993) 975-980
6. Nagamitsu A., Greish K., and Maeda H. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 39 (2009) 756-766
7. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46 (1986) 6387-6392
8. Raat N.J.H., Shiva S., and Gladwin M.T. Effects of nitrite on modulating ROS generation following ischemia and reperfusion. Adv. Drug Deliv. Rev. 61 (2009) 339-350
9. Wu J., Akaike T., and Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58 (1998) 159-165
10. Maeda H., Noguchi Y., Sato K., and Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85 (1994) 331-334
11. 3]bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263 (1988) 16051-16054
12. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. In: Weber G. (Ed). Advances in Enzyme Regulation (2001), Elsevier Science Ltd, Oxford 189-207
13. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Review: Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control. Release 65 (2000) 271-284
14. Greish K., Fang J., Inuzuka T., Nagamitsu A., and Maeda H. Macromolecular anticancer therapeutics for effective solid tumor targeting: advantages and prospects. Clin. Pharmacokinet. 42 (2003) 1089-1105
15. Maeda H., Bharate G.Y., and Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm. 71 (2009) 409-419
16. Seki T., Fang J., and Maeda H. Tumor-targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. In: Lu Y., and Mahato R.I. (Eds). Pharmaceutical Perspectives of Cancer Therapeutics (2009), Springer Publishing Co., New York 93-120
17. Fukuto J.M., Cho J.Y., and Switzer C.H. The chemical properties of nitric oxide and related nitrogen oxides. In: Ignarro L.J. (Ed). Nitric oxide: biology and pathobiology (2000), Academic Press, San Diego, CA 23-39
18. Feelisch M., and Noack E.A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol. 139 (1987) 19-30
19. Jordan B.F., Misson P.D., Demeure R., et al. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 565-570
20. Mitchell J.B., Wink D.A., DeGraff W., et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 53 (1993) 5845-5848
21. Maeda H., Seki T., and Fang J. Enhanced tumor delivery of macromolecular antitumor drug by topical applications of nitroglycerine on superficial tumors. Proc. 67th Annual Meeting of the Japanese Cancer Association. Abstract vol. P-5184 (Oct. 28-30, 2008) 385 Nagoya, Japan
22. Seki T., Fang J., and Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100 (2009) 2426-2430 (available online, doi:10.1111/j.1349-7006.2009.01323.x)
23. Yasuda H., Yamaya M., Nakayama K., et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 24 (2006) 688-694
24. Yasuda H., Nakayama K., Watanabe M., et al. Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma. Clin. Cancer Res. 12 (2006) 6748-6757
25. Yasuda H., Yanagihara K., Nakayama K., et al. Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. In: Bonavida B. (Ed). Nitric Oxide and Cancer (2009), Springer Science, New York
26. Siemens D.R., Heaton J.P.W., Adams M.A., Kawakami J., and Graham C.H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 74 (2009) 878-883
27. Kitagaki J., Yang Y., Saavedra J.E., et al. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53. Oncogene 28 (2009) 619-624
28. Udupi V., Yu M., Malaviya S., Saavedra J.E., and Shami P.J. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells. Leuk. Res. 30 (2006) 1279-1283
29. Shami P.J., Saavedra J.E., Bonifant C.L., et al. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. J. Med. Chem. 49 (2006) 4356-4366
30. Liu J., Li C., Qu W., et al. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation. Mol. Cancer Ther. 3 (2004) 709-714
31. Shami P.J., Saavedra J.E., and Wang L.Y. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol. Cancer Ther. 2 (2003) 409-417
32. Ren Z., Kar S., Wang Z., Wang M., Saavedra J.E., and Carr B.I. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. J. Cell. Physiol. 197 (2003) 426-434
33. Maeda H., Wu J., Okamoto T., Maruo K., and Akaike T. Kallikrein-kinin in infection and cancer. Immunopharmacology 43 (1999) 115-128
34. Molla A., Yamamoto T., Akaike T., Miyoshi S., and Maeda H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 264 (1989) 10589-10594
35. Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., and Maeda H. Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 2448-2453
36. Fang J., Iyer A.K., Seki T., Nakamura H., Greish K., and Maeda H. SMA-copolymer conjugate of AHPP: a polymeric inhibitor of xanthine oxidase with potential antihypertensive effect. J. Control. Release 135 (2009) 211-217